Oncoclínicas stock faces pressure as OPA dispute widens

Oncoclínicas stock faces a new legal challenge as the Brazilian cancer-care group manages a disputed mandatory tender offer and a fresh request to change its board. On September 30, 2026, UBS Lumen asked for a shareholder meeting to remove and elect board members, according to Valor Econômico.

Shareholder dispute expands

The UBS Lumen proposal adds a governance issue to the tender-offer dispute. The fund holds 55,966,951 ordinary shares, equal to 4.93 percent of the company in circulation, and the company said the request remained under review on September 30, 2026, according to Valor Econômico.

A separate civil action seeks compensation for current and former shareholders who bought the stock in the initial public offering or on the secondary market. According to Investing.com on September 29, 2026, the claim also seeks BRL 50,000 per current or former shareholder, while the company said no ruling on the merits had been issued.

Losses expose balance sheet strain

The legal pressure comes against a weak second-quarter financial backdrop. Net revenue fell 28.5 percent year over year to BRL 1.1 billion, while the net loss widened to BRL 475.7 million from BRL 142.3 million, according to O Globo.

In a separate assessment of the second quarter, Oncoclínicas had BRL 112.0 million in cash, BRL 3.39 billion in short-term financial debt, and negative accounting EBITDA of BRL 245.6 million, according to Eu Quero Investir. That contrast makes the OPA primarily a shareholder event rather than a direct source of cash for the company.

Market value remains compressed

On September 30, 2026, Oncoclínicas had a market capitalization of BRL 1.1 billion on B3. The stock's 52-week range was BRL 0.53 to BRL 3.91, placing governance, liquidity and the outcome of the tender-offer dispute at the center of the equity story.